S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Surmodics Stock Forecast, Price & News

+1.07 (+2.33%)
(As of 01/14/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
41,928 shs
Average Volume
51,136 shs
Market Capitalization
$657.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

Surmodics logo

About Surmodics

SurModics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.


Surmodics (NASDAQ:SRDX) Could Easily Take On More Debt
December 30, 2021 |  finance.yahoo.com
Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat
November 12, 2021 |  finance.yahoo.com
Surmodics Inc (SRDX) Q4 2021 Earnings Call Transcript
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$105.14 million
Cash Flow
$0.96 per share
Book Value
$10.10 per share


Net Income
$4.24 million
Pretax Margin




Free Float
Market Cap
$657.90 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.23 out of 5 stars

Medical Sector

340th out of 1,405 stocks

Surgical & Medical Instruments Industry

39th out of 129 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Surmodics (NASDAQ:SRDX) Frequently Asked Questions

Is Surmodics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surmodics stock.
View analyst ratings for Surmodics
or view top-rated stocks.

How has Surmodics' stock price been impacted by Coronavirus (COVID-19)?

Surmodics' stock was trading at $29.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SRDX stock has increased by 57.3% and is now trading at $47.06.
View which stocks have been most impacted by COVID-19

Are investors shorting Surmodics?

Surmodics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 253,600 shares, an increase of 17.6% from the December 15th total of 215,700 shares. Based on an average daily volume of 50,500 shares, the short-interest ratio is currently 5.0 days. Currently, 1.9% of the shares of the stock are short sold.
View Surmodics' Short Interest

When is Surmodics' next earnings date?

Surmodics is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Surmodics

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. The business had revenue of $23.97 million for the quarter, compared to the consensus estimate of $22.46 million. Surmodics had a net margin of 4.03% and a trailing twelve-month return on equity of 3.76%. During the same quarter last year, the business posted ($0.18) EPS.
View Surmodics' earnings history

What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY 2022 earnings guidance on Wednesday, December, 8th. The company provided EPS guidance of $-1.750-$-1.250 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.920. The company issued revenue guidance of $97 million-$101 million, compared to the consensus revenue estimate of $118.12 million.

What price target have analysts set for SRDX?

2 Wall Street analysts have issued 12-month price objectives for Surmodics' shares. Their forecasts range from $70.00 to $70.00. On average, they expect Surmodics' share price to reach $70.00 in the next year. This suggests a possible upside of 48.7% from the stock's current price.
View analysts' price targets for Surmodics
or view top-rated stocks among Wall Street analysts.

Who are Surmodics' key executives?

Surmodics' management team includes the following people:

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics CEO Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among Surmodics' employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Who are Surmodics' major shareholders?

Surmodics' stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Diversified Trust Co (0.06%). Company insiders that own Surmodics stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, Gary R Maharaj, John D Manders, Jose H Bedoya, Joseph J Stich and Joseph J Stich.
View institutional ownership trends for Surmodics

Which major investors are selling Surmodics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Surmodics company stock in the last year include Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, and Joseph J Stich.
View insider buying and selling activity for Surmodics
or view top insider-selling stocks.

Which major investors are buying Surmodics stock?

SRDX stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for Surmodics
or or view top insider-buying stocks.

How do I buy shares of Surmodics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $47.06.

How much money does Surmodics make?

Surmodics has a market capitalization of $657.90 million and generates $105.14 million in revenue each year. The company earns $4.24 million in net income (profit) each year or $0.30 on an earnings per share basis.

How many employees does Surmodics have?

Surmodics employs 370 workers across the globe.

When was Surmodics founded?

Surmodics was founded in 1979.

What is Surmodics' official website?

The official website for Surmodics is www.surmodics.com.

Where are Surmodics' headquarters?

Surmodics is headquartered at 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at (952) 500-7000, via email at [email protected], or via fax at 952-500-7001.

This page was last updated on 1/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.